ProCE Banner Activity

Daratumumab Combinations Increase MRD Negativity vs Rd or Vd Alone in Relapsed/Refractory Multiple Myeloma

Slideset Download
Conference Coverage
Addition of daratumumab to either Rd or Vd significantly increased MRD-negative responses even in high-risk patients with relapsed/refractory multiple myeloma.

Released: December 05, 2016

Expiration: December 04, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen